Health1 min read

STAT+: FDA approves new breast cancer drug, providing new option for some patients, boost for Roche

By · Via STAT Health · Published by Everything Blog

In short

The clearance applies to patients with HR-positive, HER2-negative advanced breast cancer carrying an ESR1 mutation, a biomarker associated with tumors developing resistance to standard therapies. Known chemically as giredestrant, the selective estrogen receptor degrader prolonged the time before disease progression in the evERA trial. The regulatory milestone reinforces Roche's longstanding oncology footprint established via its subsidiary Genentech and the legacy drug Herceptin.

Key points

  • Roche anticipates that the newly authorized breast cancer medication could eventually bec…: Roche anticipates that the newly authorized breast cancer medication could eventually become its top-selling product.
  • The presence of the targeted ESR1 gene mutation indicates a patient's cancer is resisting…: The presence of the targeted ESR1 gene mutation indicates a patient's cancer is resisting conventional treatments.
  • The regulatory clearance helps Roche defend its market position against intensifying onco…: The regulatory clearance helps Roche defend its market position against intensifying oncology competition from rival drugmakers.

Sources checked by our analysis pipeline: 1

The Food and Drug Administration on Monday approved a new breast cancer drug from Roche, teeing up the launch of a medicine that the Swiss company has said could become its top-selling product ever.

The approval of Wilserdly, also known as giredestrant, was one of the most important regulatory decisions Roche had been awaiting. It also gives the company another foothold in breast cancer treatments, a field in which it has a storied history with the drug Herceptin through its subsidiary Genentech, though in recent years it’s fallen behind rival pharma companies in oncology.

The approval is specifically for patients with HR-positive, HER2-negative advanced breast cancer that has picked up a mutation in the ESR1 gene, a sign that the tumor is developing resistance to standard treatments. The evERA trial showed that the drug, an oral treatment known as a selective estrogen receptor degrader, or SERD, extended the time period before patients’ tumors progressed.

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already…

Health